1 completed. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Completed 1 |
Follow Sciensano: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine immunogenicity after first and second dose - Covid19 | Phase 4 | Completed | Sciensano | 145 | 2021-05-10 | 2023-03-28 |
COVID-19 (1)
Belgium (1)